Paul-Henry Schmelck
Nessuna posizione attualmente
Profilo
Dr. Paul-Henry Schmelck, MD, is Directeur de Participations at OTC Asset Management SA in France.
He received his doctorate degree from Université Paris, and a graduate degree from Université Paris.
Precedenti posizioni note di Paul-Henry Schmelck
| Società | Posizione | Fine |
|---|---|---|
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Direttore/Membro del Consiglio | 08/03/2010 |
Apicap SAS
 Apicap SAS Investment ManagersFinance Apicap SAS is a Venture Capital firm, a subsidiary of OTC Holding SAS founded in 2001. Apicap SAS is headquartered in Paris. | Investitore di Private Equity | 01/10/2009 |
PrimeBioTech
 PrimeBioTech Medical DistributorsDistribution Services PrimeBioTech develops therapeutic products based on gene therapy technologies. The private company is based in Paris, France. | Presidente | 01/01/2004 |
| NANOBIOTIX | Corporate Officer/Principal | - |
| NEOVACS | Direttore/Membro del Consiglio | - |
Formazione di Paul-Henry Schmelck
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| SANOFI | Health Technology |
| NEOVACS | Health Technology |
| NANOBIOTIX | Health Technology |
| Aziende private | 3 |
|---|---|
Apicap SAS
Apicap SAS Investment ManagersFinance Apicap SAS is a Venture Capital firm, a subsidiary of OTC Holding SAS founded in 2001. Apicap SAS is headquartered in Paris. | Finance |
PrimeBioTech
PrimeBioTech Medical DistributorsDistribution Services PrimeBioTech develops therapeutic products based on gene therapy technologies. The private company is based in Paris, France. | Distribution Services |
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
- Borsa valori
- Insiders
- Paul-Henry Schmelck
